#### IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION

MDL No. 2776

United States Judicial Panel on Multidistrict Litigation.

April 6, 2017

Before Sarah S. Vance, Chair, Marjorie O. Rendell, Charles R. Breyer, Lewis A. Kaplan, R. David Proctor, Catherine D. Perry, Judges of the Panel.

TRANSFER ORDER

SARAH S. VANCE, Chair

Before the Panel:* Plaintiff in an action *1381*(Aron)*pending in the Southern District of New York moves to centralize eighteen actions in that district or, in the alternative, the Eastern District of Pennsylvania or the Southern District of Illinois. As listed on the attached Schedules A and B, thirteen of the actions are pending in the Southern District of New York, with one action each in the Southern District of Alabama, the Southern District of Illinois, the Eastern District of Louisiana, the Northern District of Mississippi, and the Eastern District of Pennsylvania. The Panel has been informed of five additional federal actions involving related issues.

The eighteen actions involve allegations that ingestion of the drug Farxiga may cause a variety, of injuries, including diabetic ketoacidosis and kidney damage, and that defendants Bristol-Myers Squibb Co., AstraZeneca Pharmaceuticals LP, As-traZeneca LP, AstraZeneca PLC, and As-traZeneca AB (collectively, Bristol-Myers/AstraZeneca), which developed, manufactured, and marketed the drugs, failed to adequately test the drugs and warn of their risks. Farxiga and its sister drug Xigduo XR1 belong to a class of diabetes drugs known as Sodium Glucose Cotransporter 2 (SGLT2) inhibitors. Other SLGT2 inhibitors include Invokana (cana-gliflozin) and Jardiance (empagliflozin). Of the eighteen actions, only one, the Eastern District of Pennsylvania *Seay*action, is a so-called “combination case”—an action involving ingestion of not only Farxi-ga and Xigduo XR but also Invokana. *(Seay*is listed on the attached Schedule B.)

All, responding plaintiffs support centralization. Bristol-Myers/AstraZeneca opposes centralization, and, if an MDL is created, opposes inclusion of any combination cases such as *Seay*in the MDL.2 Also, if the Panel orders céntralization, Bristol-Myers/AstraZeneca argues for selection of the District of Delaware or the Southern District of New York as transferee district. Defendant Janssen Pharmaceuticals, Inc. (Janssen), which makes Invokana and is sued only in *Seay,*takes no position on centralization, but argues that if an MDL is created, the Panel should treat any “combination cases” such as *Seay*as it did in centralizing the Invokana litigation this past *December—ie.,*separating and remanding claims involving other SLGT2 inhibitors to their respective transferor courts. In addition, Janssen notes that because *Seay*was removed from state court on Class Action Fairness Act (CAFA) “mass action” grounds, it cannot be transferred to another district under Section 1407, absent a request by the *Seay*plaintiff.3

On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and that centralization of these cases *1382will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. The actions share factual questions arising from allegations that taking Farxiga or Xigduo XR may result in patients suffering kidney-related injuries, such as diabetic ke-toacidosis and kidney damage. The actions thus implicate numerous common issues concerning the development, manufacture, testing, regulatory history, promotion, and labeling of the drugs. Centralization will eliminate duplicative discovery, prevent inconsistent pretrial rulings on *Daubert*issues and other pretrial matters, and conserve the resources of the parties, their counsel, and the judiciary.

We select the Southern District of New York as transferee district for this litigation. Bristol-Myers Squibb Co. is headquartered in New York, and thus many witnesses and relevant documents are likely to be found in or near the district. In addition, thirteen of the constituent actions are pending in that district, as are four tag-along actions. Finally, centralization in the Southern District of New York enables us to assign the litigation to Judge Loma G. Schofield, an able and experienced jurist who has not had the opportunity to preside over an MDL. Judge Schofield already is presiding over the constituent and tag-along actions pending in the district, and- we are confident that she will steer this litigation on a prudent course.

IT IS THEREFORE ORDERED that the actions listed ón Schedule A and pending outside the Southern District of New York are transferred to the Southern District of New York, and, with the consent of that court, assigned to the Honorable Lorna G. Schofield for coordinated or consolidated pretrial proceedings.

IT IS FURTHER ORDERED that transfer of the *Seay*action listed on Schedule B is denied.

■ SCHEDULE A

MDL No. 2776 — IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION

> Southern District of Alabama

> FORAN v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-, 00471

> Southern District of Illinois

> BLEDSOE v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 3:16-01295

> Eastern District,of Louisiana

> MOORE v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 2:16-16809

> Northern District of Mississippi

> YOUNG v. BRISTOL-MYERS SQUIBB CO., ET AL., Q.A. No. 4:16-00108

> Southern District of New York

> WARNER v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-08187

> HUDSON, ET AL. v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A No. 1:16-08888

> POPWELL v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-08915

> DOTY, ET AL. V. BRISTOL-MEYERS SQUIBB CO., ET AL., C.A. No. 1:16-08951

> PONCE v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-08959

> FOWLER, ET AL. v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-08960

> *1383PEREZ, ET AL. v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-08961

> PROSSER v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-08962

> BURKETT, ET AL. v. BRISTOL-MYERS SQUIBB CO., ET AL, C.A. No. 1:16-08986

> ASSAVEDO v. BRISTOL-MYERS SQUIBB CO., ET AL, C.A. No. 1:16-09330

> COLLINS v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-09722

> ARON v. BRISTOL-MYERS SQUIBB CO, ET AL., C.A. No. 1:16-10003

> CORMIER v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 1:16-10046

SCHEDULE B

MDL No. 2776 — IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION

> Eastern District of Pennsylvania

> SEAY v. JANSSEN PHARMACEUTICALS, INC., ET AL., C.A. No. 2:16-05946

*

 Judge Ellen Segal Huvelle took no part in the decision of this matter.

1

. The active ingredient in Farxiga is dapagli-flozin, while Xigduo XR contains both dapa-gliflozin and metformin.

2

. The issue of inclusion in the proposed MDL of the Invokana-related claims in *Seay is*moot, as those claims recently were transferred to MDL No. 2750, In re: Invokana (Canagliflozin) Products Liability Litigation, which is pending in the District of New Jersey.

3

. *See*28 U.S.C. § 1332(d)(ll)(C)(i) ("Any action(s) removed to Federal court pursuant to this subsection shall not thereafter be transferred to any other court pursuant to section 1407, or the rules promulgated thereunder, unless a majority of the plaintiffs in the action request transfer pursuant to section 1407.”). We agree with Janssen, and therefore will not transfer the Farxiga and Xigduo XR claims in *Seay*at this time. We note that the *Seay*plaintiff earlier requested transfer of his Invokana claims to MDL No. 2750, and that those claims were transferred, via an unopposed conditional transfer order, on March 29, 2017.